The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma
Authors
Keywords
-
Journal
OncoImmunology
Volume 2, Issue 5, Pages e24436
Publisher
Informa UK Limited
Online
2013-05-10
DOI
10.4161/onci.24436
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2012
- (2012) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- A randomized phase 2 study of temozolomide and bevacizumab ornab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma
- (2012) Lisa A. Kottschade et al. CANCER
- VEGFA-VEGFR Pathway Blockade Inhibits Tumor-Induced Regulatory T-cell Proliferation in Colorectal Cancer
- (2012) M. Terme et al. CANCER RESEARCH
- The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
- (2011) M J M Gooden et al. BRITISH JOURNAL OF CANCER
- Interleukin 6 mediates production of interleukin 10 in metastatic melanoma
- (2011) Mizue Terai et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma
- (2011) James S. Wilmott et al. CLINICAL CANCER RESEARCH
- BEAM: A Randomized Phase II Study Evaluating the Activity of Bevacizumab in Combination With Carboplatin Plus Paclitaxel in Patients With Previously Untreated Advanced Melanoma
- (2011) Kevin B. Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma
- (2010) Lisa A. Kottschade et al. CANCER
- A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients
- (2010) Olivier Adotevi et al. JOURNAL OF IMMUNOTHERAPY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evidence of Systemic Th2-Driven Chronic Inflammation in Patients with Metastatic Melanoma
- (2009) W. K. Nevala et al. CLINICAL CANCER RESEARCH
- Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
- (2009) J. S. Ko et al. CLINICAL CANCER RESEARCH
- Novel therapeutics for the treatment of metastatic melanoma
- (2009) Aaron S Mansfield et al. Future Oncology
- Three Phase II Cytokine Working Group Trials of gp100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients With HLA-A2–Positive Advanced Melanoma
- (2008) Jeffrey A. Sosman et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
- (2008) Alexander MM Eggermont et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started